Article info

Original research
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells

Authors

  1. Correspondence to Dr Alexander Kamb; akamb{at}a2biotherapeutics.com
View Full Text

Citation

Tokatlian T, Asuelime GE, Mock J, et al
Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells

Publication history

  • Accepted December 20, 2021
  • First published January 28, 2022.
Online issue publication 
October 18, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.